Quince Therapeutics appoints Brendan Hannah as COO, effective Oct 24, 2023

Quince Therapeutics, Inc.

Brendan Hannah, age 38, appointed COO; continues as Chief Business Officer and principal financial/accounting officer.
Granted option to purchase 75,000 shares at $0.99, vesting over 48 months from Oct 23, 2023.
Served as Chief Business Officer since May 2022; previously COO of Novosteo Inc.
No family relationships or transactions requiring disclosure under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brendan Hannah

Chief Operating Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2023-10-24
Filed: October 26, 2023, 7:59 PM ET

On October 24, 2023, the Board of Directors of Quince Therapeutics, Inc. (the “Company”) appointed Brendan Hannah to the position of Chief Operating Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan Hannah was appointed as Chief Operating Officer at Quince Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On October 24, 2023, the Board of Directors of Quince Therapeutics, Inc. (the “Company”) appointed Brendan Hannah to the position of Chief Operating Officer of the Company.

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-264057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.